openPR Logo
Press release

Colorectal Cancer Pipeline Assessment | In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies

08-17-2022 07:29 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Colorectal Cancer Pipeline

Colorectal Cancer Pipeline

As per DelveInsight's assessment, globally, nearly 150+ key pharma and biotech companies are working on 150+ pipeline drugs in the Colorectal Cancer therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA) and molecule types. Several of the therapies are in the advanced stages of clinical development expected to launch in the coming years.

"Colorectal Cancer Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Colorectal Cancer Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Download the sample pages:
https://www.delveinsight.com/report-store/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Colorectal Cancer Pipeline Analysis
The report provides insights into:
• The report provides detailed insights about companies that are developing therapies in the Colorectal Cancer Market.
• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Colorectal Cancer treatment.
• Colorectal Cancer key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Colorectal Cancer Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Colorectal Cancer market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Request for Sample PDF:
https://www.delveinsight.com/report-store/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Colorectal Cancer Therapeutics Analysis
There are approx. 150+ key companies which are developing therapies for Colorectal Cancer. Currently, Mirati Therapeutics has its Colorectal Cancer drug candidates in the most advanced stage of clinical development.

Colorectal Cancer Therapies covered in the report include:
Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio Zrt, AskAt, Effector Therapeutics, Menarini Group, ImmunityBio, Arcus Biosciences, Chia Tai Tianqing Pharmaceutical Group, Aadi, LLC, MacroGenics, Amgen, BioNTech SE, Novartis, Immunovative Therapies, Transgene, Cardiff Oncology, Genentech, Sumitomo Dainippon Pharma, GamaMabs Pharma, Qilu Pharmaceutical, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., PharmaMar, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, Sinomab, Yooyoung Pharmaceutical, Amal Therapeutics, Merck Sharp & Dohme Corp., AstraZeneca, Isofol Medical, Surgimab, EpicentRx, Inc, Apros Therapeutics, Eisai Co., Ltd., Pregen ShenZhen Biotechnology, Puma Biotechnology, G1 Therapeutics, Mologen AG, Sumitomo Dainippon Pharma, Celyad Oncology, Nitto BioPharma, Jiangsu HengRui Medicine, Evelo Biosciences, Sinocelltech, Sichuan Kelun Pharmaceutical Research Institute, Nektar Therapeutics, MedPacto, Karyopharm Therapeutics, Gritstone Oncology, Lumicell, Inc., IDEAYA Biosciences, Cantargia AB, NextCure, Inc., Lokon Pharma AB, AbGenomics B.V, Chongqing Precision Biotech Co., Ltd, Bold Therapeutics, OBI Pharma, Inc, Gritstone Oncology, IGM Biosciences, Rgenix, Inc., Precision Biologics, Inc. and Others

Colorectal Cancer Therapies covered in the report include:
• Patritumab Deruxtecan (Daiichi Sankyo Company)
• Adagrasib (Mirati Therapeutics)
• Etrumadenant (Arcus Bioscience)
• AL2846 (Advenchen Laboratories)
• Onvansertib (Cardiff Oncology)
And many more

Request the Sample PDF to Get a more in-depth Assessment:
https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Colorectal Cancer Current Treatment Patterns
4. Colorectal Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Colorectal Cancer Late Stage Products (Phase-III)
7. Colorectal Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Colorectal Cancer Discontinued Products
13. Colorectal Cancer Product Profiles
14. Colorectal Cancer Key Companies
15. Colorectal Cancer Key Products
16. Dormant and Discontinued Products
17. Colorectal Cancer Unmet Needs
18. Colorectal Cancer Future Perspectives
19. Colorectal Cancer Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.

Request for the Sample PDF (to get a detailed understanding of the TOC, Tables, and Figures included in the report), at: https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Anuj Rawat
Email: info@delveinsight.com
https://www.delveinsight.com/
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Colorectal Cancer Pipeline Assessment | In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies here

News-ID: 2706553 • Views:

More Releases from DelveInsight Business Research

Androgenetic Alopecia Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Follicum AB, Cassiopea, Inc.
Androgenetic Alopecia Market and Epidemiology 2032: Treatment Market, Therapies, …
The Androgenetic Alopecia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Androgenetic Alopecia pipeline products will significantly revolutionize the Androgenetic Alopecia market dynamics. DelveInsight's "Androgenetic Alopecia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Androgenetic Alopecia, historical and forecasted epidemiology as well as the Androgenetic Alopecia market trends in the United
Dravet Syndrome Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Takeda, Eisai, Stoke Therapeutics, EpyGenix Therapeutics, Marinus Pharma, Stoke Therapeutics, Inc, Jazz Pharma
Dravet Syndrome Market is Predicted to Exhibit Remarkable Growth During the Fore …
DelveInsight's "Dravet Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Dravet Syndrome, historical and forecasted epidemiology as well as the Dravet Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Dravet Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dravet Syndrome Market Forecast https://www.delveinsight.com/sample-request/dravet-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the
Syphilis Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Mayne Pharma
Syphilis Market to Register Incremental Growth During the Forecast Period (2023- …
DelveInsight's "Syphilis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Syphilis, historical and forecasted epidemiology as well as the Syphilis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Syphilis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Syphilis Market Forecast https://www.delveinsight.com/sample-request/syphilis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key facts of the Syphilis
Leigh Syndrome Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | PTC Therapeutics, Abliva AB
Leigh Syndrome Market to Witness Upsurge in Growth During the Forecast Period (2 …
The Leigh Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Leigh Syndrome pipeline products will significantly revolutionize the Leigh Syndrome market dynamics. DelveInsight's "Leigh Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Leigh Syndrome, historical and forecasted epidemiology as well as the Leigh Syndrome market trends in the United

All 5 Releases


More Releases for Colorectal

Potential Opportunities of Colorectal Cancer Therapeutics Market
The global colorectal cancer therapeutics market size is projected to reach USD 16.58 billion by 2026, owing to the rise in the prevalence of colorectal cancer worldwide. A report by Fortune Business Insights(TM) titled, "Colorectal Cancer Therapeutics Market Size, Share & Industry Analysis, By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy, Others), By Cancer Type (Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and
Colorectal Cancer Pipeline Therapeutic Review H1 2017
Colorectal Cancer Pipeline Review H1 2017 provides an overview of the Colorectal Cancer (Oncology) pipeline landscape. Colorectal cancer is cancer that starts in the large intestine (Colorectal). There is no single cause of colorectal cancer. Nearly all colorectal cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. For More on Colorectal Cancer Pipeline Review H1 2017 Report Inquire @ https://goo.gl/1HQ4Fn . Report Description: Pharmaceutical guide Colorectal Cancer - Pipeline Review H1
US Colorectal Cancer Drug Pipeline Analysis
Among all the regions affected with colorectal cancer, the US would continue to account for a giant’s share owing to its huge population base. With regards to rates of increase, it is most likely that the US would witness a modest increase in the prevalence of the disease, mostly as a result of the country having already reached epidemic proportions of the disease. According to estimates, approximately 55,000 people die
Colorectal Cancer - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Colorectal Cancer - Heat Map and Analysis to its growing collection of premium market research reports. Colorectal cancer (CRC), otherwise known as bowel cancer, is a malignancy originating in the colon (the large intestine) or rectum, both of which are located towards the end of the human gastrointestinal tract. It begins as a benign tumor, which is almost always in
In-vitro Colorectal Cancer Screening Tests Market to Reach US$980.6 mn by 2023, …
A research report on the global in-vitro colorectal cancer screening tests market for by Transparency Market Research (TMR) estimates this market to expand at a CAGR of 7.50% during the period from 2015 and 2023. In 2014, the market stood at US$494.1 mn and it is projected reach a value of US$980.6 mn by the end of the forecast period.The research report is titled “In-vitro Colorectal Cancer Screening Tests Market
Colorectal Cancer Treatment Market- Global Outlook 2024
Colorectal cancer is cancer that starts in the colon or rectum. The colon and the rectum are parts of the large intestine, which is the lower part of the body’s digestive system. The colon absorbs water and nutrients from the food and stores waste matter (stool). Stool moves from the colon into the rectum before it leaves the body. Colorectal cancer often begins as a growth called a polyp, which